BC Extra | Aug 7, 2015
Financial News

Cold Genesys raises $10M in series B

Cold Genesys Inc. (Santa Ana, Calif.) raised $10 million in a series B round co-led by existing investor Ally Bridge Group and new investor WI Harper Group. New investors Whitesun Healthcare Ventures and Song Hong...
BC Innovations | May 21, 2015
Product R&D

Aduro's STING

Aduro Biotech Inc. 's preclinical STING agonists have caught the eye of pharmas for their ability to stimulate immunity in distal tumors, which suggests the compounds might be among the first immunotherapy agents for metastases....
BC Week In Review | Jul 28, 2014
Clinical News

GVAX Pancreas cancer vaccine regulatory update

Aduro said FDA granted breakthrough therapy designation to the combination of CRS-207 and GVAX Pancreas cancer vaccine to treat pancreatic cancer. The designation was based on data from a Phase II trial of the combination...
BC Week In Review | Jul 28, 2014
Clinical News

CRS-207 regulatory update

Aduro said FDA granted breakthrough therapy designation to the combination of CRS-207 and GVAX Pancreas cancer vaccine to treat pancreatic cancer. The designation was based on data from a Phase II trial of the combination...
BC Week In Review | Jul 14, 2014
Company News

RestorGenex Corp management update

RestorGenex Corp . (OTCQB:RESX), Los Angeles, Calif.   Business: Cancer, Dermatology, Ophthalmic   Hired: Phillip Donenberg as CFO, formerly SVP of finance, CFO and secretary of BioSante Pharmaceuticals Inc. , now part of ANI Pharmaceuticals Inc.  ...
BC Week In Review | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol transdermal gel is approved in the U.S. to treat moderate to severe hot flashes and night sweats associated with...
BC Week In Review | Mar 17, 2014
Company News

RestorGenex management update

RestorGenex Corp. (OTCQB:SMDI), Los Angeles, Calif.   Business: Dermatology, Ophthalmic   Hired: Stephen Simes as CEO, formerly president, CEO and vicechairman of BioSante Pharmaceuticals Inc. , now ANI Pharmaceuticals Inc. ; he succeeds Jerold Rubinstein, who...
BC Week In Review | Feb 17, 2014
Clinical News

CRS-207: Phase IIb started

Aduro began the open-label, North American Phase IIb ECLIPSE trial to compare CRS-207 plus GVAX Pancreas cancer vaccine and low-dose cyclophosphamide vs. CRS-207 alone or chemotherapy in about 240 previously treated metastatic pancreatic cancer patients....
BC Week In Review | Feb 17, 2014
Clinical News

GVAX Pancreas cancer vaccine: Phase IIb started

Aduro began the open-label, North American Phase IIb ECLIPSE trial to compare CRS-207 plus GVAX Pancreas cancer vaccine and low-dose cyclophosphamide vs. CRS-207 alone or chemotherapy in about 240 previously treated metastatic pancreatic cancer patients....
BC Week In Review | Feb 10, 2014
Clinical News

CRS-207: Updated Phase II data

Updated data from an open-label, U.S. Phase II trial in 93 patients with metastatic pancreatic cancer showed that CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide led to a median OS, the primary endpoint, of...
Items per page:
1 - 10 of 248
BC Extra | Aug 7, 2015
Financial News

Cold Genesys raises $10M in series B

Cold Genesys Inc. (Santa Ana, Calif.) raised $10 million in a series B round co-led by existing investor Ally Bridge Group and new investor WI Harper Group. New investors Whitesun Healthcare Ventures and Song Hong...
BC Innovations | May 21, 2015
Product R&D

Aduro's STING

Aduro Biotech Inc. 's preclinical STING agonists have caught the eye of pharmas for their ability to stimulate immunity in distal tumors, which suggests the compounds might be among the first immunotherapy agents for metastases....
BC Week In Review | Jul 28, 2014
Clinical News

GVAX Pancreas cancer vaccine regulatory update

Aduro said FDA granted breakthrough therapy designation to the combination of CRS-207 and GVAX Pancreas cancer vaccine to treat pancreatic cancer. The designation was based on data from a Phase II trial of the combination...
BC Week In Review | Jul 28, 2014
Clinical News

CRS-207 regulatory update

Aduro said FDA granted breakthrough therapy designation to the combination of CRS-207 and GVAX Pancreas cancer vaccine to treat pancreatic cancer. The designation was based on data from a Phase II trial of the combination...
BC Week In Review | Jul 14, 2014
Company News

RestorGenex Corp management update

RestorGenex Corp . (OTCQB:RESX), Los Angeles, Calif.   Business: Cancer, Dermatology, Ophthalmic   Hired: Phillip Donenberg as CFO, formerly SVP of finance, CFO and secretary of BioSante Pharmaceuticals Inc. , now part of ANI Pharmaceuticals Inc.  ...
BC Week In Review | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol transdermal gel is approved in the U.S. to treat moderate to severe hot flashes and night sweats associated with...
BC Week In Review | Mar 17, 2014
Company News

RestorGenex management update

RestorGenex Corp. (OTCQB:SMDI), Los Angeles, Calif.   Business: Dermatology, Ophthalmic   Hired: Stephen Simes as CEO, formerly president, CEO and vicechairman of BioSante Pharmaceuticals Inc. , now ANI Pharmaceuticals Inc. ; he succeeds Jerold Rubinstein, who...
BC Week In Review | Feb 17, 2014
Clinical News

CRS-207: Phase IIb started

Aduro began the open-label, North American Phase IIb ECLIPSE trial to compare CRS-207 plus GVAX Pancreas cancer vaccine and low-dose cyclophosphamide vs. CRS-207 alone or chemotherapy in about 240 previously treated metastatic pancreatic cancer patients....
BC Week In Review | Feb 17, 2014
Clinical News

GVAX Pancreas cancer vaccine: Phase IIb started

Aduro began the open-label, North American Phase IIb ECLIPSE trial to compare CRS-207 plus GVAX Pancreas cancer vaccine and low-dose cyclophosphamide vs. CRS-207 alone or chemotherapy in about 240 previously treated metastatic pancreatic cancer patients....
BC Week In Review | Feb 10, 2014
Clinical News

CRS-207: Updated Phase II data

Updated data from an open-label, U.S. Phase II trial in 93 patients with metastatic pancreatic cancer showed that CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide led to a median OS, the primary endpoint, of...
Items per page:
1 - 10 of 248